O'Halloran D J, Jones P M, Ghatei M A, Bloom S R
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London.
J Endocrinol. 1991 Dec;131(3):411-9. doi: 10.1677/joe.0.1310411.
Prolactin secretion is highly regulable, and the possibility exists that there are local intrapituitary factors controlling prolactin secretion. Recently, the neuropeptides vasoactive intestinal peptide (VIP), galanin and substance P (SP) have been co-localized to the lactotroph in the female rat. We investigated the effects of alterations in prolactin status in vivo on pituitary and hypothalamic expression of these peptides by specific radioimmunoassays and mRNA analysis. In the anterior pituitary, following haloperidol treatment, the contents of both VIP and galanin were suppressed to below detectable levels. Similarly, after bromocriptine treatment, the content of VIP was decreased to below the detection limit of the assay while galanin (14.2 +/- 1.3 vs control 21.0 +/- 2.1 fmol/mg, P less than 0.05) also showed a significant reduction. The levels of VIP mRNA and galanin mRNA in these groups showed the same qualitative change as their respective peptides. Concurrent treatment with high-dose oestrogen modified the VIP peptide response to bromocriptine (1368.7 +/- 149.2 vs bromocriptine 843.4 +/- 82.7 fmol/mg, P less than 0.05) but not to haloperidol. Oestrogen-induced decreases in galanin content were not influenced by either treatment. The pituitary content of SP showed a fall after oestrogen treatment (1.1 +/- 0.01 vs control 6.4 +/- 0.8 fmol/mg, P less than 0.05) which was not significantly altered by either bromocriptine or haloperidol. Likewise, SP mRNA levels in the pituitary were decreased by 90% following oestrogen treatment. Hypothalamic expression of these peptides did not change with any of the treatments.(ABSTRACT TRUNCATED AT 250 WORDS)
催乳素分泌具有高度可调节性,垂体内部可能存在控制催乳素分泌的局部因素。最近,在雌性大鼠中发现神经肽血管活性肠肽(VIP)、甘丙肽和P物质(SP)与催乳细胞共同定位。我们通过特异性放射免疫分析和mRNA分析,研究了体内催乳素状态改变对这些肽在垂体和下丘脑表达的影响。在前垂体中,氟哌啶醇治疗后,VIP和甘丙肽的含量均被抑制至检测水平以下。同样,溴隐亭治疗后,VIP含量降至检测限以下,而甘丙肽(14.2±1.3对对照组21.0±2.1 fmol/mg,P<0.05)也显著降低。这些组中VIP mRNA和甘丙肽mRNA的水平与其各自肽的变化具有相同的定性变化。高剂量雌激素同时治疗改变了VIP肽对溴隐亭的反应(1368.7±149.2对溴隐亭843.4±82.7 fmol/mg,P<0.05),但对氟哌啶醇无影响。雌激素诱导的甘丙肽含量降低不受任何一种治疗的影响。雌激素治疗后垂体中SP的含量下降(1.1±0.01对对照组6.4±0.8 fmol/mg,P<0.05),溴隐亭或氟哌啶醇对此均无显著改变。同样,雌激素治疗后垂体中SP mRNA水平下降了90%。这些肽在下丘脑的表达在任何一种治疗后均未改变。(摘要截短至250字)